1 | values | 30,253 |
2 | t-scores | 84 |
3 | adc-1500 | 16 |
4 | tympanograms | 16 |
5 | nadirs | 14 |
6 | snfl | 12 |
7 | jeunesse® | 9 |
8 | heterozygosities | 8 |
9 | ec50s | 6 |
10 | life-spans | 5 |
11 | mmg-f | 5 |
12 | pq-interval | 5 |
13 | 3.1a | 4 |
14 | /vc | 3 |
15 | cinetocardiograms | 3 |
16 | downshifts | 3 |
17 | ewls | 3 |
18 | q-values | 3 |
19 | risk-category | 3 |
20 | ,22 | 2 |
21 | .restenosis | 2 |
22 | 0.10mg/ml | 2 |
23 | 10500 | 2 |
24 | 300μg/ml | 2 |
25 | 7.5-8.5 | 2 |
26 | 8.0-11.0 | 2 |
27 | basicola | 2 |
28 | h-scores | 2 |
29 | hla-allele | 2 |
30 | inflexus | 2 |
31 | mecoprop-p | 2 |
32 | n-excretion | 2 |
33 | seperately | 2 |
34 | ter331 | 2 |
35 | valores | 2 |
36 | w14-3-inu-112 | 2 |
37 | δhus | 2 |
38 | σ-complexes | 2 |
39 | ≥7.7 | 2 |
40 | 0.34±0.03μm | 1 |
41 | 0.668-0.675 | 1 |
42 | 0.86/0.87 | 1 |
43 | 1.63-1.70-fold | 1 |
44 | 1420c | 1 |
45 | 149.37 | 1 |
46 | 2.4μm | 1 |
47 | 24-hsbp | 1 |
48 | 3-iodothiophenes | 1 |
49 | 3-oxoisoxazole-2 | 1 |
50 | 4-26μg/ml | 1 |
51 | 4-acyl-2-acylamino-5- | 1 |
52 | 4.7-8.5 | 1 |
53 | 5.77-6.30 | 1 |
54 | 6-aminopyrimidin-4 | 1 |
55 | 6.2-7.2 | 1 |
56 | 6.779 | 1 |
57 | 64.4μg/ml | 1 |
58 | 82.43 | 1 |
59 | alone.we | 1 |
60 | aminobenzanthrones | 1 |
61 | assessment.improvement | 1 |
62 | at19.5μg/ml | 1 |
63 | comparisons.pyrexia | 1 |
64 | consta® | 1 |
65 | ctrttrcc13003732 | 1 |
66 | curli-deficient | 1 |
67 | estacas | 1 |
68 | gfr-gfr | 1 |
69 | group. | 1 |
70 | heterocycles-oxazolyl-1,3,4-oxadiazoles | 1 |
71 | immunosorber | 1 |
72 | levels-were | 1 |
73 | list-fatigue | 1 |
74 | megaslope | 1 |
75 | micro-/nanomanipulations | 1 |
76 | number-to-treat | 1 |
77 | pm2.5-values | 1 |
78 | risk-assessments | 1 |
79 | square=12.7±1 | 1 |
80 | square=13.38 | 1 |
81 | squared=20.8 | 1 |
82 | squared=22.6 | 1 |
83 | squared=9.7 | 1 |
84 | thiirane | 1 |
1 | ,22 | 2 |
2 | .restenosis | 2 |
3 | /vc | 3 |
4 | 0.10mg/ml | 2 |
5 | 0.34±0.03μm | 1 |
6 | 0.668-0.675 | 1 |
7 | 0.86/0.87 | 1 |
8 | 1.63-1.70-fold | 1 |
9 | 10500 | 2 |
10 | 1420c | 1 |
11 | 149.37 | 1 |
12 | 2.4μm | 1 |
13 | 24-hsbp | 1 |
14 | 3-iodothiophenes | 1 |
15 | 3-oxoisoxazole-2 | 1 |
16 | 3.1a | 4 |
17 | 300μg/ml | 2 |
18 | 4-26μg/ml | 1 |
19 | 4-acyl-2-acylamino-5- | 1 |
20 | 4.7-8.5 | 1 |
21 | 5.77-6.30 | 1 |
22 | 6-aminopyrimidin-4 | 1 |
23 | 6.2-7.2 | 1 |
24 | 6.779 | 1 |
25 | 64.4μg/ml | 1 |
26 | 7.5-8.5 | 2 |
27 | 8.0-11.0 | 2 |
28 | 82.43 | 1 |
29 | adc-1500 | 16 |
30 | alone.we | 1 |
31 | aminobenzanthrones | 1 |
32 | assessment.improvement | 1 |
33 | at19.5μg/ml | 1 |
34 | basicola | 2 |
35 | cinetocardiograms | 3 |
36 | comparisons.pyrexia | 1 |
37 | consta® | 1 |
38 | ctrttrcc13003732 | 1 |
39 | curli-deficient | 1 |
40 | downshifts | 3 |
41 | ec50s | 6 |
42 | estacas | 1 |
43 | ewls | 3 |
44 | gfr-gfr | 1 |
45 | group. | 1 |
46 | h-scores | 2 |
47 | heterocycles-oxazolyl-1,3,4-oxadiazoles | 1 |
48 | heterozygosities | 8 |
49 | hla-allele | 2 |
50 | immunosorber | 1 |
51 | inflexus | 2 |
52 | jeunesse® | 9 |
53 | levels-were | 1 |
54 | life-spans | 5 |
55 | list-fatigue | 1 |
56 | mecoprop-p | 2 |
57 | megaslope | 1 |
58 | micro-/nanomanipulations | 1 |
59 | mmg-f | 5 |
60 | n-excretion | 2 |
61 | nadirs | 14 |
62 | number-to-treat | 1 |
63 | pm2.5-values | 1 |
64 | pq-interval | 5 |
65 | q-values | 3 |
66 | risk-assessments | 1 |
67 | risk-category | 3 |
68 | seperately | 2 |
69 | snfl | 12 |
70 | square=12.7±1 | 1 |
71 | square=13.38 | 1 |
72 | squared=20.8 | 1 |
73 | squared=22.6 | 1 |
74 | squared=9.7 | 1 |
75 | t-scores | 84 |
76 | ter331 | 2 |
77 | thiirane | 1 |
78 | tympanograms | 16 |
79 | valores | 2 |
80 | values | 30,253 |
81 | w14-3-inu-112 | 2 |
82 | δhus | 2 |
83 | σ-complexes | 2 |
84 | ≥7.7 | 2 |
1 | 4-acyl-2-acylamino-5- | 1 |
2 | group. | 1 |
3 | 8.0-11.0 | 2 |
4 | 10500 | 2 |
5 | adc-1500 | 16 |
6 | 5.77-6.30 | 1 |
7 | ter331 | 2 |
8 | square=12.7±1 | 1 |
9 | 3-oxoisoxazole-2 | 1 |
10 | 6.2-7.2 | 1 |
11 | w14-3-inu-112 | 2 |
12 | ,22 | 2 |
13 | ctrttrcc13003732 | 1 |
14 | 82.43 | 1 |
15 | 6-aminopyrimidin-4 | 1 |
16 | 7.5-8.5 | 2 |
17 | 4.7-8.5 | 1 |
18 | 0.668-0.675 | 1 |
19 | squared=22.6 | 1 |
20 | ≥7.7 | 2 |
21 | squared=9.7 | 1 |
22 | 149.37 | 1 |
23 | 0.86/0.87 | 1 |
24 | squared=20.8 | 1 |
25 | square=13.38 | 1 |
26 | 6.779 | 1 |
27 | 3.1a | 4 |
28 | comparisons.pyrexia | 1 |
29 | basicola | 2 |
30 | 1420c | 1 |
31 | /vc | 3 |
32 | 1.63-1.70-fold | 1 |
33 | hla-allele | 2 |
34 | thiirane | 1 |
35 | megaslope | 1 |
36 | levels-were | 1 |
37 | list-fatigue | 1 |
38 | alone.we | 1 |
39 | mmg-f | 5 |
40 | pq-interval | 5 |
41 | snfl | 12 |
42 | 0.10mg/ml | 2 |
43 | 300μg/ml | 2 |
44 | 64.4μg/ml | 1 |
45 | at19.5μg/ml | 1 |
46 | 4-26μg/ml | 1 |
47 | 0.34±0.03μm | 1 |
48 | 2.4μm | 1 |
49 | n-excretion | 2 |
50 | mecoprop-p | 2 |
51 | 24-hsbp | 1 |
52 | immunosorber | 1 |
53 | gfr-gfr | 1 |
54 | ec50s | 6 |
55 | estacas | 1 |
56 | heterozygosities | 8 |
57 | heterocycles-oxazolyl-1,3,4-oxadiazoles | 1 |
58 | 3-iodothiophenes | 1 |
59 | aminobenzanthrones | 1 |
60 | h-scores | 2 |
61 | t-scores | 84 |
62 | valores | 2 |
63 | values | 30,253 |
64 | pm2.5-values | 1 |
65 | q-values | 3 |
66 | σ-complexes | 2 |
67 | .restenosis | 2 |
68 | ewls | 3 |
69 | cinetocardiograms | 3 |
70 | tympanograms | 16 |
71 | life-spans | 5 |
72 | micro-/nanomanipulations | 1 |
73 | nadirs | 14 |
74 | downshifts | 3 |
75 | risk-assessments | 1 |
76 | δhus | 2 |
77 | inflexus | 2 |
78 | number-to-treat | 1 |
79 | curli-deficient | 1 |
80 | assessment.improvement | 1 |
81 | seperately | 2 |
82 | risk-category | 3 |
83 | consta® | 1 |
84 | jeunesse® | 9 |